VolitionRX (VNRX) falls 0.66% in Light Trading on January 14

Equities Staff  |

VolitionRX Ltd (NYSE: VNRX) shares fell 0.66%, or $0.02 per share, to close Friday at $3.02. After opening the day at $3.01, shares of VolitionRX fluctuated between $3.09 and $3.00. 68,450 shares traded hands a decrease from their 30 day average of 108,886. Friday's activity brought VolitionRX’s market cap to $161,679,206.

About VolitionRX Ltd

Volition is a multi-national epigenetics company developing simple, easy to use, costeffective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

Visit VolitionRX Ltd’s profile for more information.

About The New York Stock Exchange

The New York Stock Exchange is the world’s largest stock exchange by market value at over $26 trillion. It is also the leader for initial public offerings, with $82 billion raised in 2020, including six of the seven largest technology deals. 63% of SPAC proceeds in 2020 were raised on the NYSE, including the six largest transactions.

To get more information on VolitionRX Ltd and to follow the company’s latest updates, you can visit the company’s profile page here: VolitionRX Ltd’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Commodities Post Strongest Gains in Over a Decade
Charlie Munger Doubles Down on Alibaba While the Fed Signals Tightening
Commodities — Assessing 2021 and Forecasting 2022

Market Movers

Sponsored Financial Content